Zytiga (abiraterone/prednisone) have a very high degree of cross resistance and cannot be used in sequence for a long-term management strategy for Prostate cancer. Xtandi (AstelllaslPfizer), approved for treatment of metastatic castration-resistant prostate cancer (mCRPC) is a nonsteroidal antiandrogen